Bi-specific antibodies against tim-3 and pd-1 for immunotherapy in chronic immune conditions
AssigneeThe Brigham and Women's Hospital, Inc.
InventorsVijay K. Kuchroo, Ana C. Anderson
Life of this patent
Estimating the term…
Abstract
Described herein are novel compositions comprising bispecific and multispecific polypeptide agents, and methods using these agents for targeting cells, such as functionally exhausted or unresponsive immune cells, that co-express the inhibitory receptors PD-1 and TIM-3. These compositions and methods are useful for the treatment of chronic immune conditions, such as persistent infections or cancer.
Claims29
A multispecific polypeptide agent comprising at least one binding site that specifically binds to a PD-1 molecule, and at least one binding site that specifically binds to a TIM-3 molecule.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
A method of treating a subject having a chronic immune condition, the method comprising administering to a subject having a chronic immune condition an effective amount of a multispecific polypeptide agent comprising at least one binding site that specifically binds to a PD-1 molecule, and at least one binding site that specifically binds to a TIM-3 molecule.
A method of activating an immune response in a subject having a chronic immune condition, the method comprising administering to a subject having a chronic immune condition an effective amount of a multispecific polypeptide agent comprising at least one binding site that specifically binds to a PD-1 molecule, and at least one binding site that specifically binds to a TIM-3 molecule.
Dependencies are inferred from the claim text.